C

Cyfuse Biomedical KK
TSE:4892

Watchlist Manager
Cyfuse Biomedical KK
TSE:4892
Watchlist
Price: 640 JPY -1.54% Market Closed
Market Cap: ¥6.1B

Operating Margin

-1 018.4%
Current
Improving
by 79.3%
vs 3-y average of -1 097.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 018.4%
=
Operating Income
¥-671m
/
Revenue
¥65.9m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 018.4%
=
Operating Income
¥-671m
/
Revenue
¥65.9m

Peer Comparison

Country Company Market Cap Operating
Margin
JP
Cyfuse Biomedical KK
TSE:4892
6.1B JPY
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
233.5B USD
Loading...
US
Danaher Corp
NYSE:DHR
166.5B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
82.9T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
37.9B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
41B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
274.7B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
38.2B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
29.1B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
19.2B EUR
Loading...

Market Distribution

Lower than 99% of companies in Japan
Percentile
1st
Based on 6 730 companies
1st percentile
-1 018.4%
Low
-125 500% — 4.2%
Typical Range
4.2% — 10.6%
High
10.6% — 9 743.7%
Distribution Statistics
Japan
Min -125 500%
30th Percentile 4.2%
Median 7%
70th Percentile 10.6%
Max 9 743.7%

Cyfuse Biomedical KK
Glance View

Cyfuse Biomedical KK develops and manufactures cell regenerative systems. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2022-12-01. The firm is engaged in the development of pipelines for obtaining approval for regenerative medicine products and contract research cell products in the field of regenerative medicine. The firm is engaged in the development of cell products as tools for drug discovery support for pharmaceutical companies in the drug discovery support field. The firm is engaged in the development and sell of three-dimensional cell stacking system equipment equipped with basic technology, apply technology for cell product development, and develop new technology in the device field.

Intrinsic Value
71.94 JPY
Overvaluation 89%
Intrinsic Value
Price
C
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 018.4%
=
Operating Income
¥-671m
/
Revenue
¥65.9m
What is Cyfuse Biomedical KK's current Operating Margin?

The current Operating Margin for Cyfuse Biomedical KK is -1 018.4%, which is above its 3-year median of -1 097.7%.

How has Operating Margin changed over time?

Over the last 3 years, Cyfuse Biomedical KK’s Operating Margin has decreased from -113.5% to -1 018.4%. During this period, it reached a low of -1 645.9% on Dec 31, 2024 and a high of -113.5% on Dec 1, 2022.

Back to Top